Literature DB >> 20064928

Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.

Flavio Curnis1, Angela Cattaneo, Renato Longhi, Angelina Sacchi, Anna Maria Gasparri, Fabio Pastorino, Paola Di Matteo, Catia Traversari, Angela Bachi, Mirco Ponzoni, Gian-Paolo Rizzardi, Angelo Corti.   

Abstract

Various NGR-containing peptides have been exploited for targeted delivery of drugs to CD13-positive tumor neovasculature. Recent studies have shown that compounds containing this motif can rapidly deamidate and generate isoaspartate-glycine-arginine (isoDGR), a ligand of alphavbeta3-integrin that can be also exploited for drug delivery to tumors. We have investigated the role of NGR and isoDGR peptide scaffolds on their biochemical and biological properties. Peptides containing the cyclic CNGRC sequence could bind CD13-positive endothelial cells more efficiently than those containing linear GNGRG. Peptide degradation studies showed that cyclic peptides mostly undergo NGR-to-isoDGR transition and CD13/integrin switching, whereas linear peptides mainly undergo degradation reactions involving the alpha-amino group, which generate non-functional six/seven-membered ring compounds, unable to bind alphavbeta3, and small amount of isoDGR. Structure-activity studies showed that cyclic isoDGR could bind alphavbeta3 with an affinity >100-fold higher than that of linear isoDGR and inhibited endothelial cell adhesion and tumor growth more efficiently. Cyclic isoDGR could also bind other integrins (alphavbeta5, alphavbeta6, alphavbeta8, and alpha5beta1), although with 10-100-fold lower affinity. Peptide linearization caused loss of affinity for all integrins and loss of specificity, whereas alpha-amino group acetylation increased the affinity for all tested integrins, but caused loss of specificity. These results highlight the critical role of molecular scaffold on the biological properties of NGR/isoDGR peptides. These findings may have important implications for the design and development of anticancer drugs or tumor neovasculature-imaging compounds, and for the potential function of different NGR/isoDGR sites in natural proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20064928      PMCID: PMC2838331          DOI: 10.1074/jbc.M109.044297

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms.

Authors:  Flavio Curnis; Anna Gasparri; Angelina Sacchi; Angela Cattaneo; Fulvio Magni; Angelo Corti
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

2.  Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models.

Authors:  A Gasparri; M Moro; F Curnis; A Sacchi; S Pagano; F Veglia; G Casorati; A G Siccardi; P Dellabona; A Corti
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

3.  Aminopeptidase N/CD13 targeting fluorescent probes: synthesis and application to tumor cell imaging.

Authors:  Zhouen Zhang; Hiroshi Harada; Kazuhito Tanabe; Hiroshi Hatta; Masahiro Hiraoka; Sei-ichi Nishimoto
Journal:  Peptides       Date:  2005-11       Impact factor: 3.750

4.  Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.

Authors:  Paola Di Matteo; Flavio Curnis; Renato Longhi; Giorgio Colombo; Angelina Sacchi; Luca Crippa; Maria Pia Protti; Mirco Ponzoni; Salvatore Toma; Angelo Corti
Journal:  Mol Immunol       Date:  2005-12-07       Impact factor: 4.407

5.  Anti-cancer activity of targeted pro-apoptotic peptides.

Authors:  H M Ellerby; W Arap; L M Ellerby; R Kain; R Andrusiak; G D Rio; S Krajewski; C R Lombardo; R Rao; E Ruoslahti; D E Bredesen; R Pasqualini
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

6.  Design and synthesis of a bimodal target-specific contrast agent for angiogenesis.

Authors:  Anouk Dirksen; Sander Langereis; Bas F M de Waal; Marcel H P van Genderen; E W Meijer; Quido G de Lussanet; Tilman M Hackeng
Journal:  Org Lett       Date:  2004-12-23       Impact factor: 6.005

7.  Tumor-specific gene delivery mediated by a novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13.

Authors:  Stanley Moffatt; Sandra Wiehle; Richard J Cristiano
Journal:  Hum Gene Ther       Date:  2005-01       Impact factor: 5.695

8.  Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.

Authors:  Ralf Bieker; Torsten Kessler; Christian Schwöppe; Teresa Padró; Thorsten Persigehl; Christoph Bremer; Johannes Dreischalück; Astrid Kolkmeyer; Walter Heindel; Rolf M Mesters; Wolfgang E Berdel
Journal:  Blood       Date:  2009-01-28       Impact factor: 22.113

9.  Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma.

Authors:  Anna Maria Gasparri; Elena Jachetti; Barbara Colombo; Angelina Sacchi; Flavio Curnis; Gian-Paolo Rizzardi; Catia Traversari; Matteo Bellone; Angelo Corti
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

10.  Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.

Authors:  Yumi Yokoyama; Sundaram Ramakrishnan
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

View more
  32 in total

1.  Synthesis and evaluation of novel Tc-99m labeled probestin conjugates for imaging APN/CD13 expression in vivo.

Authors:  Gopal Pathuri; Andria F Hedrick; Bryan C Disch; John T Doan; Michael A Ihnat; Vibhudutta Awasthi; Hariprasad Gali
Journal:  Bioconjug Chem       Date:  2011-12-20       Impact factor: 4.774

Review 2.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

3.  Chromogranin A binds to αvβ6-integrin and promotes wound healing in mice.

Authors:  Flavio Curnis; Anna Maria Gasparri; Renato Longhi; Barbara Colombo; Silvia D'Alessio; Fabio Pastorino; Mirco Ponzoni; Angelo Corti
Journal:  Cell Mol Life Sci       Date:  2012-03-14       Impact factor: 9.261

4.  De novo design of a tumor-penetrating peptide.

Authors:  Luca Alberici; Lise Roth; Kazuki N Sugahara; Lilach Agemy; Venkata R Kotamraju; Tambet Teesalu; Claudio Bordignon; Catia Traversari; Gian-Paolo Rizzardi; Erkki Ruoslahti
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

5.  The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms.

Authors:  Simona Porcellini; Claudia Asperti; Barbara Valentinis; Elena Tiziano; Patrizia Mangia; Claudio Bordignon; Gian-Paolo Rizzardi; Catia Traversari
Journal:  Oncoimmunology       Date:  2015-07-01       Impact factor: 8.110

6.  αV integrins in Schwann cells promote attachment to axons, but are dispensable in vivo.

Authors:  Kathleen K Catignas; Luciana R Frick; Marta Pellegatta; Edward Hurley; Zachary Kolb; Kathryn Addabbo; Joseph H McCarty; Richard O Hynes; Arjan van der Flier; Yannick Poitelon; Lawrence Wrabetz; Maria Laura Feltri
Journal:  Glia       Date:  2020-08-03       Impact factor: 7.452

7.  Protein L-isoaspartyl methyltransferase regulates p53 activity.

Authors:  Jae-Cheol Lee; Sung-Ung Kang; Yeji Jeon; Jong Woo Park; Jueng-Soo You; Shin-Won Ha; Narkhyun Bae; Gert Lubec; So Hee Kwon; Ju-Seog Lee; Eun-Jung Cho; Jeung-Whan Han
Journal:  Nat Commun       Date:  2012-06-26       Impact factor: 14.919

8.  Oxidation-induced structural changes of ceruloplasmin foster NGR motif deamidation that promotes integrin binding and signaling.

Authors:  Marco Barbariga; Flavio Curnis; Andrea Spitaleri; Annapaola Andolfo; Chiara Zucchelli; Massimo Lazzaro; Giuseppe Magnani; Giovanna Musco; Angelo Corti; Massimo Alessio
Journal:  J Biol Chem       Date:  2013-12-23       Impact factor: 5.157

9.  Glycine N-methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing.

Authors:  Angelo Corti; Anna Maria Gasparri; Michela Ghitti; Angelina Sacchi; Francesco Sudati; Martina Fiocchi; Valentina Buttiglione; Laura Perani; Alessandro Gori; Silvia Valtorta; Rosa Maria Moresco; Fabio Pastorino; Mirco Ponzoni; Giovanna Musco; Flavio Curnis
Journal:  Adv Funct Mater       Date:  2017-09-26       Impact factor: 18.808

10.  NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors.

Authors:  Flavio Curnis; Martina Fiocchi; Angelina Sacchi; Alessandro Gori; Anna Gasparri; Angelo Corti
Journal:  Nano Res       Date:  2016-03-04       Impact factor: 8.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.